Agricultural Inputs
Compare Stocks
5 / 10Stock Comparison
SEED vs CTVA vs SANW vs FMC vs AMGN
Revenue, margins, valuation, and 5-year total return — side by side.
Agricultural Inputs
Agricultural Farm Products
Agricultural Inputs
Drug Manufacturers - General
SEED vs CTVA vs SANW vs FMC vs AMGN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Agricultural Inputs | Agricultural Inputs | Agricultural Farm Products | Agricultural Inputs | Drug Manufacturers - General |
| Market Cap | $9M | $53.08B | $43K | $1.71B | $177.59B |
| Revenue (TTM) | $102M | $17.89B | $38M | $3.43B | $37.24B |
| Net Income (TTM) | $-43M | $1.16B | $-32M | $-2.50B | $7.80B |
| Gross Margin | 5.5% | 33.5% | 20.9% | 35.3% | 71.5% |
| Operating Margin | -72.6% | 13.8% | -44.5% | -59.5% | 31.6% |
| Forward P/E | — | 21.6x | — | 7.7x | 14.7x |
| Total Debt | $54M | $2.58B | $54M | $4.20B | $54.60B |
| Cash & Equiv. | $16M | $4.52B | $294K | $585M | $9.13B |
SEED vs CTVA vs SANW vs FMC vs AMGN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Origin Agritech Lim… (SEED) | 100 | 31.3 | -68.7% |
| Corteva, Inc. (CTVA) | 100 | 289.5 | +189.5% |
| S&W Seed Company (SANW) | 100 | 0.0 | -100.0% |
| FMC Corporation (FMC) | 100 | 13.9 | -86.1% |
| Amgen Inc. (AMGN) | 100 | 143.3 | +43.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: SEED vs CTVA vs SANW vs FMC vs AMGN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
SEED lags the leaders in this set but could rank higher in a more targeted comparison.
CTVA carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- 186.7% 10Y total return vs AMGN's 156.4%
- Lower volatility, beta 0.29, Low D/E 10.6%, current ratio 1.43x
- PEG 1.81 vs AMGN's 5.01
- Beta 0.29, yield 0.9%, current ratio 1.43x
Among these 5 stocks, SANW doesn't own a clear edge in any measured category.
FMC ranks third and is worth considering specifically for dividends.
- 17.0% yield, 7-year raise streak, vs AMGN's 2.9%, (2 stocks pay no dividend)
AMGN is the #2 pick in this set and the best alternative if income & stability and growth exposure is your priority.
- Dividend streak 15 yrs, beta 0.60, yield 2.9%
- Rev growth 9.9%, EPS growth 88.2%, 3Y rev CAGR 11.8%
- 9.9% revenue growth vs SEED's -20.5%
- 20.9% margin vs SANW's -85.4%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.9% revenue growth vs SEED's -20.5% | |
| Value | PEG 1.81 vs 5.01 | |
| Quality / Margins | 20.9% margin vs SANW's -85.4% | |
| Stability / Safety | Beta 0.29 vs FMC's 1.63, lower leverage | |
| Dividends | 17.0% yield, 7-year raise streak, vs AMGN's 2.9%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +27.7% vs SANW's -99.6% | |
| Efficiency (ROA) | 8.6% ROA vs SANW's -46.3%, ROIC 14.8% vs -12.0% |
SEED vs CTVA vs SANW vs FMC vs AMGN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
SEED vs CTVA vs SANW vs FMC vs AMGN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
AMGN leads in 2 of 6 categories
CTVA leads 2 • SEED leads 0 • SANW leads 0 • FMC leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
AMGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMGN is the larger business by revenue, generating $37.2B annually — 986.2x SANW's $38M. AMGN is the more profitable business, keeping 20.9% of every revenue dollar as net income compared to SANW's -85.4%. On growth, SEED holds the edge at +75.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $102M | $17.9B | $38M | $3.4B | $37.2B |
| EBITDAEarnings before interest/tax | -$74M | $3.4B | -$14M | -$1.9B | $15.6B |
| Net IncomeAfter-tax profit | -$43M | $1.2B | -$32M | -$2.5B | $7.8B |
| Free Cash FlowCash after capex | -$40M | $2.1B | $497,701 | -$91M | $8.6B |
| Gross MarginGross profit ÷ Revenue | +5.5% | +33.5% | +20.9% | +35.3% | +71.5% |
| Operating MarginEBIT ÷ Revenue | -72.6% | +13.8% | -44.5% | -59.5% | +31.6% |
| Net MarginNet income ÷ Revenue | -42.6% | +6.5% | -85.4% | -72.9% | +20.9% |
| FCF MarginFCF ÷ Revenue | -39.0% | +11.5% | +1.3% | -2.7% | +23.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +75.7% | +11.0% | +2.0% | -4.1% | +5.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -3.4% | +12.6% | +57.7% | -17.8% | +4.4% |
Valuation Metrics
CTVA leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 23.1x trailing earnings, AMGN trades at a 53% valuation discount to CTVA's 49.4x P/E. Adjusting for growth (PEG ratio), CTVA offers better value at 4.14x vs AMGN's 7.86x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $9M | $53.1B | $43,117 | $1.7B | $177.6B |
| Enterprise ValueMkt cap + debt − cash | $14M | $51.1B | $54M | $5.3B | $223.1B |
| Trailing P/EPrice ÷ TTM EPS | -1.10x | 49.42x | -0.00x | -0.77x | 23.12x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 21.57x | — | 7.74x | 14.74x |
| PEG RatioP/E ÷ EPS growth rate | — | 4.14x | — | — | 7.86x |
| EV / EBITDAEnterprise value multiple | — | 13.38x | — | — | 14.08x |
| Price / SalesMarket cap ÷ Revenue | 0.64x | 3.05x | 0.00x | 0.49x | 4.83x |
| Price / BookPrice ÷ Book value/share | — | 2.18x | 0.00x | 0.82x | 20.60x |
| Price / FCFMarket cap ÷ FCF | — | 18.86x | — | — | 21.92x |
Profitability & Efficiency
AMGN leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
AMGN delivers a 89.4% return on equity — every $100 of shareholder capital generates $89 in annual profit, vs $-120 for SANW. CTVA carries lower financial leverage with a 0.11x debt-to-equity ratio, signaling a more conservative balance sheet compared to AMGN's 6.31x. On the Piotroski fundamental quality scale (0–9), AMGN scores 7/9 vs FMC's 2/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | +4.6% | -120.2% | -82.3% | +89.4% |
| ROA (TTM)Return on assets | -42.3% | +2.7% | -46.3% | -23.0% | +8.6% |
| ROICReturn on invested capital | — | +8.5% | -12.0% | -21.2% | +14.8% |
| ROCEReturn on capital employed | — | +8.6% | -26.8% | -25.9% | +16.0% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 3 | 2 | 7 |
| Debt / EquityFinancial leverage | — | 0.11x | 1.21x | 2.00x | 6.31x |
| Net DebtTotal debt minus cash | $38M | -$1.9B | $54M | $3.6B | $45.5B |
| Cash & Equiv.Liquid assets | $16M | $4.5B | $294,014 | $585M | $9.1B |
| Total DebtShort + long-term debt | $54M | $2.6B | $54M | $4.2B | $54.6B |
| Interest CoverageEBIT ÷ Interest expense | -23.25x | 5.82x | -3.41x | -0.24x | 5.02x |
Total Returns (Dividends Reinvested)
CTVA leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CTVA five years ago would be worth $16,828 today (with dividends reinvested), compared to $3 for SANW. Over the past 12 months, CTVA leads with a +27.7% total return vs SANW's -99.6%. The 3-year compound annual growth rate (CAGR) favors AMGN at 15.0% vs SANW's -90.8% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -1.7% | +17.0% | -71.3% | -4.0% | +1.2% |
| 1-Year ReturnPast 12 months | -1.7% | +27.7% | -99.6% | -57.1% | +22.8% |
| 3-Year ReturnCumulative with dividends | -81.7% | +40.8% | -99.9% | -82.5% | +51.9% |
| 5-Year ReturnCumulative with dividends | -91.4% | +68.3% | -100.0% | -80.2% | +46.2% |
| 10-Year ReturnCumulative with dividends | -93.2% | +186.7% | -100.0% | -26.8% | +156.4% |
| CAGR (3Y)Annualised 3-year return | -43.2% | +12.1% | -90.8% | -44.0% | +15.0% |
Risk & Volatility
Evenly matched — CTVA and SANW each lead in 1 of 2 comparable metrics.
Risk & Volatility
SANW is the less volatile stock with a -3.79 beta — it tends to amplify market swings less than FMC's 1.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CTVA currently trades 92.3% from its 52-week high vs SANW's 0.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.94x | 0.29x | -3.79x | 1.63x | 0.60x |
| 52-Week HighHighest price in past year | $2.49 | $85.63 | $6.00 | $44.78 | $391.29 |
| 52-Week LowLowest price in past year | $0.74 | $60.54 | $0.00 | $12.17 | $261.43 |
| % of 52W HighCurrent price vs 52-week peak | +45.8% | +92.3% | +0.3% | +30.5% | +84.1% |
| RSI (14)Momentum oscillator 0–100 | 43.9 | 53.3 | 28.6 | 43.4 | 39.4 |
| Avg Volume (50D)Average daily shares traded | 93K | 3.4M | 686 | 3.2M | 2.5M |
Analyst Outlook
Evenly matched — FMC and AMGN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CTVA as "Buy", FMC as "Hold", AMGN as "Buy". Consensus price targets imply 13.9% upside for FMC (target: $16) vs 6.6% for AMGN (target: $351). For income investors, FMC offers the higher dividend yield at 17.01% vs CTVA's 0.89%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | — | Hold | Buy |
| Price TargetConsensus 12-month target | — | $88.17 | — | $15.58 | $350.76 |
| # AnalystsCovering analysts | — | 37 | — | 42 | 38 |
| Dividend YieldAnnual dividend ÷ price | — | +0.9% | — | +17.0% | +2.9% |
| Dividend StreakConsecutive years of raises | 0 | 5 | — | 7 | 15 |
| Dividend / ShareAnnual DPS | — | $0.71 | — | $2.33 | $9.45 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +2.0% | 0.0% | +0.1% | 0.0% |
AMGN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CTVA leads in 2 (Valuation Metrics, Total Returns). 2 tied.
SEED vs CTVA vs SANW vs FMC vs AMGN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is SEED or CTVA or SANW or FMC or AMGN a better buy right now?
For growth investors, Amgen Inc.
(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus -20. 5% for Origin Agritech Limited (SEED). Amgen Inc. (AMGN) offers the better valuation at 23. 1x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate Corteva, Inc. (CTVA) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — SEED or CTVA or SANW or FMC or AMGN?
On trailing P/E, Amgen Inc.
(AMGN) is the cheapest at 23. 1x versus Corteva, Inc. at 49. 4x. On forward P/E, FMC Corporation is actually cheaper at 7. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Corteva, Inc. wins at 1. 81x versus Amgen Inc. 's 5. 01x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — SEED or CTVA or SANW or FMC or AMGN?
Over the past 5 years, Corteva, Inc.
(CTVA) delivered a total return of +68. 3%, compared to -100. 0% for S&W Seed Company (SANW). Over 10 years, the gap is even starker: CTVA returned +186. 7% versus SANW's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — SEED or CTVA or SANW or FMC or AMGN?
By beta (market sensitivity over 5 years), S&W Seed Company (SANW) is the lower-risk stock at -3.
79β versus FMC Corporation's 1. 63β — meaning FMC is approximately -143% more volatile than SANW relative to the S&P 500. On balance sheet safety, Corteva, Inc. (CTVA) carries a lower debt/equity ratio of 11% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — SEED or CTVA or SANW or FMC or AMGN?
By revenue growth (latest reported year), Amgen Inc.
(AMGN) is pulling ahead at 9. 9% versus -20. 5% for Origin Agritech Limited (SEED). On earnings-per-share growth, the picture is similar: Amgen Inc. grew EPS 88. 2% year-over-year, compared to -757. 4% for FMC Corporation. Over a 3-year CAGR, SEED leads at 19. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — SEED or CTVA or SANW or FMC or AMGN?
Amgen Inc.
(AMGN) is the more profitable company, earning 21. 0% net margin versus -64. 6% for FMC Corporation — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus -58. 9% for SEED. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is SEED or CTVA or SANW or FMC or AMGN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Corteva, Inc. (CTVA) is the more undervalued stock at a PEG of 1. 81x versus Amgen Inc. 's 5. 01x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, FMC Corporation (FMC) trades at 7. 7x forward P/E versus 21. 6x for Corteva, Inc. — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FMC: 13. 9% to $15. 58.
08Which pays a better dividend — SEED or CTVA or SANW or FMC or AMGN?
In this comparison, FMC (17.
0% yield), AMGN (2. 9% yield), CTVA (0. 9% yield) pay a dividend. SEED, SANW do not pay a meaningful dividend and should not be held primarily for income.
09Is SEED or CTVA or SANW or FMC or AMGN better for a retirement portfolio?
For long-horizon retirement investors, S&W Seed Company (SANW) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -3.
79)). FMC Corporation (FMC) carries a higher beta of 1. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SANW: -100. 0%, FMC: -26. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between SEED and CTVA and SANW and FMC and AMGN?
These companies operate in different sectors (SEED (Basic Materials) and CTVA (Basic Materials) and SANW (Consumer Defensive) and FMC (Basic Materials) and AMGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: SEED is a small-cap quality compounder stock; CTVA is a mid-cap quality compounder stock; SANW is a small-cap quality compounder stock; FMC is a small-cap income-oriented stock; AMGN is a mid-cap quality compounder stock. CTVA, FMC, AMGN pay a dividend while SEED, SANW do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.